The World Health Organization (WHO) forecasts that people most vulnerable to Covid-19, such as the elderly, will need to get an annual vaccine booster to be protected against variants, an internal document seen by Reuters shows.
The Biden administration plans to donate 500 million Pfizer coronavirus vaccine doses to nearly 100 countries over the next two years, three sources familiar with the matter told Reuters on June 9.
India’s export ban on Covid-19 shots risks dragging the battle against the pandemic “back to square one” unless wealthy nations step in to plug a gaping hole in the COVAX global vaccine-sharing scheme, health specialists said on May 20.
The global supply of Covid-19 vaccine is “incredibly tight” and the COVAX dose-sharing facility is unlikely to procure much more supply in 2021 than doses already reserved, the Gavi vaccine alliance ceo Seth Berkley said on April 15.
There is a “shocking imbalance” in the distribution of Covid-19 vaccines worldwide and most countries do not have anywhere near enough shots to cover health workers and others at high-risk, WHO Director-General Tedros Adhanom Ghebreyesus said on April 9.
The COVAX vaccine facility delivered nearly 38.4 million doses of Covid-19 vaccines to 102 countries and economies across six continents six weeks after it began to roll out supplies, according to a statement on April 8.
The world should be back to normal by the end of 2022 thanks to Covid-19 vaccines, Bill Gates said in an interview for Polish newspaper Gazeta Wyborcza and television broadcaster TVN24.
The World Health Organization-backed COVAX vaccine sharing facility has an agreement to send out “hundreds of millions” of Johnson & Johnson shots, Kate O’Brien – director of WHO’s department of immunization – said on March 17.
COVAX will deliver 237 million doses of AstraZeneca’s Covid-19 shot to 142 countries by the end of May as the World Health Organization-backed program steps up the global roll-out of its vaccine supplies.
Many health experts believe that the Covid-19 vaccine candidate NVX-CoV237 from Novavax offers potential advantages over competitors including Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca-Oxford.